Please login to the form below

PPRS

This page shows the latest PPRS news and features for those working in and with pharma, biotech and healthcare.

newly agreed 2019 Voluntary Scheme for Branded Medicines Pricing and Access (formerly known as the PPRS) and, of course, Brexit.

New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake

Decades old PPRS name to go. The UK government and the pharmaceutical industry organisation the ABPI have unveiled a new 5 year pricing deal, called the ‘Voluntary scheme for branded medicines ... The new agreement is set to come into force in January
MS and cholesterol drugs picked for new UK rapid uptake push

Two major concerns currently hovering over the sector are the ongoing renegotiation of the main pricing agreement the PPRS, as well, of course, as.
Bayer to challenge Avastin legal ruling

The row has erupted at a crucial juncture: The UK industry organisation the ABPI is in the midst of an all-important renegotiation of the PPRS pricing agreement, with the deadline
Health secretary’s ‘rip off’ remarks anger UK pharma

drugs as well as the current negotiations to replace the PPRS pricing agreement. ... with worries that the government may take similar approach in the PPRS negotiations.
ABPI hits out at ‘punitive’ UK medicines cost controls

Yesterday saw the government unveil its plans for an updated Statutory Scheme, a ‘back up’ plan for companies not in the main PPRS pricing system. ... Any souring in relations with the government on the statutory scheme would be bad news, as the two

More from news
Approximately 11 fully matching, plus 112 partially matching documents found.

The UK’s new medicines pricing deal – opportunities and risks for pharma

So what are the big differences between the 2014 PPRS and the 2019 VPAS? ... Value assessment and managing uncertainty. Value assessment was in the 2014 PPRS, and it remains in the 2019 VPAS.
The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt

It has achieved a 2% annual growth rate in the 2019 PPRS: a rate better than in each and every year of the 2014 PPRS. ... And, to me, there are three. The first is that the government has threatened the industry during every recent PPRS negotiation with
The UK’s new five-year pricing agreement

The deal, which replaces the long-standing PPRS agreement, includes a cap of 2% growth on the total medicines bill for each year of the agreement, with any NHS spending over
Comment: the new UK pricing deal – welcome news, but lessons to be learned

They have achieved a 2% annual growth rate in the 2019 PPRS: a rate better than in each and every year of the 2014 PPRS. ... And to me, there are three. The first is that the Government has threatened the industry during every recent PPRS negotiation
Brexit: can pharma 'take back control' of the narrative?

It sets a very concerning tone for the PPRS negotiations and underestimates the positive impact of R&D investment.

More from intelligence
Approximately 2 fully matching, plus 19 partially matching documents found.

EFPIA's Richard Torbett to move to the ABPI

with the Department of Health around the PPRS.”. ... At the ABPI Torbett will focus on pricing, the Pharmaceutical Price Regulation Scheme (PPRS), health technology assessments (HTA) and value assessment, as well as market access in the UK.
ABPI names Amgen’s UK head as president

of Health to secure the 2014 PPRS.
ABPI appoints value and access manager

initiatives. “These include the implementation of the new PPRS scheme, working with NICE on value based assessment and helping our members with the changing NHS landscape whilst continuing to push for
Pfizer's Jonathan Emms to be ABPI president

The UK industry is in the midst of preparing for the introduction of the new version of the Pharmaceutical Pricing Regulatory Scheme ( PPRS) in January, final details of which were published ... Emms' appointment comes after he and his company expressed

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Unique forum will unite NHS and industry to drive innovation

will be a panellist on a session about‘Negotiating the PPRS – Assessing what comes next’. . ... An overview of the agenda . Candid and open discussion about access and pricing as the deadline for completing PPRS negotiations

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Add my company

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

“Fake News” and Credibility in Medical Publishing: Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?: Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma funding and M&A in 2020: Why pharma M&A has continually bucked the trend...